CAR-T therapies see new competitors emerge in October
Danni Yin · 11/21/2022
This October, Chinese drug regulators granted the first marketing approvals to three new molecular entities (NMEs) while they expanded the labels of 12 launched drugs.
CanSino's inhaled COVID-19 vaccines gained emergency use approval in China
Danni Yin · 10/27/2022
In September, two COVID-19 vaccines received NMPA approval for emergency use: CanSino’s Convidecia Air and Livzon Pharma’s V-01. Foreign companies gained several new indications as well, including AstraZeneca’s Forxiga (dapagliflozin), Bayer’s Xarelto (rivaroxaban), Novartis’s Xolair (omalizumab) and AstraZeneca/MSD’s Lynparza (olaparib).
China approved its first homegrown CD20 antibody in August
Danni Yin · 09/19/2022
In August, China saw the approval of only one new molecular entity (NME), Sinocelltech’s CD20 antibody ripertamab (SCT400). Another two homegrown companies, Zelgen and Alphamab, gained new indications and dosing regimens for their self-developed products as well.
July sees more pan-tumor therapies approved in China
Danni Yin · 08/15/2022
China’s pursuit of innovative oncology drugs remained intense in July, as Chinese regulators granted the first marketing approval for three drugs, namely Simcere’s Cosela (trilaciclib), Lepu Biopharma’s Puyouheng (pucotenlimab) and Roche’s Rozlytrek (Entrectinib).
June approvals see China’s first greenlight based entirely on real-world data
Danni Yin · 07/18/2022
The approval of OcuMension Therapeutics’ YUTIQ was based on RWD collected in Hainan province and the phase III clinical trials that have been completed outside of China.
May approvals spotlight the rise of pediatric drugs under policy support in China
Danni Yin · 06/16/2022
Chinese regulators gave their nod to more pediatric medicines in May 2022, a move in line with the country’s commitment to supporting the development of these drugs.
Pfizer leads April approvals in China with two JAK inhibitors
Danni Yin · 05/16/2022
April 2022 saw a number of foreign and licensed drugs approved in China, with the majority of them in oncology and rheumatology.
China clears homegrown PD-1 inhibitors for solid tumors in March
Danni Yin · 04/25/2022
The month of March saw a string of approvals handed out by the NMPA, with the most significant being two domestically developed anti-PD-1 inhibitors getting green lighted to treat MSI-H/dMMR solid tumors in China for the first time ever.
China approved more drugs for atopic dermatitis in February
Danni Yin · 03/09/2022
Chinese regulators approved 11 drugs in February. Uses and indications ran a wide gamut, including two drugs for atopic dermatitis and six new molecular entities that were approved for the first time.
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback:   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement